Cisapride in chronic idiopathic constipation: clinical response and effect on colonic transit time.

Young-Tae Bak, J. H. Kim, C. H. Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVES: To evaluate the effect of cisapride on the total and segmental colonic transit times (CTT's) and on the clinical symptoms in patients with chronic idiopathic constipation, and to elucidate whether the correction of the CTT parallels the symptomatic improvement. METHODS: An open prospective trial of cisapride, 10 mg t.i.d. orally for 8 weeks, was done in 25 adult patients (M: F6: 19) with chronic idiopathic constipation of 1 year or longer duration. CTT was measured at baseline and after 8 weeks of cisapride therapy. Frequency, consistency and difficulty in passage of bowel movements were evaluated at baseline and after 2, 4 and 8 weeks of cisapride therapy. RESULTS: 19 cases continued to participate until the end of 4 weeks of therapy and 15 cases completed the entire 8 weeks' trial. No serious side effect was experienced during the study period. Total and right segmental CTT's shortened with 8 weeks of cisapride treatment. Defecation frequency increased and difficulty in stool passage improved with 2 to 8 weeks of treatment. Stool consistency had a tendency toward normal after 8 weeks of treatment (p = 0.06). The global response was excellent in 7 cases (46.7%), good in 5 (33.3%) and poor in 3 (20.0%). If all dropped-out cases were assumed to be poor responders, the good or excellent responders after 8 weeks of cisapride might be 48.0% of all recruited patients. The response to cisapride could not be predicted by the various clinical parameters of the patients. CONCLUSION: Cisapride is an effective drug in at least half of the patients with chronic idiopathic constipation.

Original languageEnglish
Pages (from-to)151-156
Number of pages6
JournalThe Korean journal of internal medicine
Volume11
Issue number2
DOIs
Publication statusPublished - 1996 Jan 1

Fingerprint

Cisapride
Constipation
Therapeutics
Defecation

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Cisapride in chronic idiopathic constipation : clinical response and effect on colonic transit time. / Bak, Young-Tae; Kim, J. H.; Lee, C. H.

In: The Korean journal of internal medicine, Vol. 11, No. 2, 01.01.1996, p. 151-156.

Research output: Contribution to journalArticle

@article{58febd0a763a4271a869540a24319c3b,
title = "Cisapride in chronic idiopathic constipation: clinical response and effect on colonic transit time.",
abstract = "OBJECTIVES: To evaluate the effect of cisapride on the total and segmental colonic transit times (CTT's) and on the clinical symptoms in patients with chronic idiopathic constipation, and to elucidate whether the correction of the CTT parallels the symptomatic improvement. METHODS: An open prospective trial of cisapride, 10 mg t.i.d. orally for 8 weeks, was done in 25 adult patients (M: F6: 19) with chronic idiopathic constipation of 1 year or longer duration. CTT was measured at baseline and after 8 weeks of cisapride therapy. Frequency, consistency and difficulty in passage of bowel movements were evaluated at baseline and after 2, 4 and 8 weeks of cisapride therapy. RESULTS: 19 cases continued to participate until the end of 4 weeks of therapy and 15 cases completed the entire 8 weeks' trial. No serious side effect was experienced during the study period. Total and right segmental CTT's shortened with 8 weeks of cisapride treatment. Defecation frequency increased and difficulty in stool passage improved with 2 to 8 weeks of treatment. Stool consistency had a tendency toward normal after 8 weeks of treatment (p = 0.06). The global response was excellent in 7 cases (46.7{\%}), good in 5 (33.3{\%}) and poor in 3 (20.0{\%}). If all dropped-out cases were assumed to be poor responders, the good or excellent responders after 8 weeks of cisapride might be 48.0{\%} of all recruited patients. The response to cisapride could not be predicted by the various clinical parameters of the patients. CONCLUSION: Cisapride is an effective drug in at least half of the patients with chronic idiopathic constipation.",
author = "Young-Tae Bak and Kim, {J. H.} and Lee, {C. H.}",
year = "1996",
month = "1",
day = "1",
doi = "10.3904/kjim.1996.11.2.151",
language = "English",
volume = "11",
pages = "151--156",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "2",

}

TY - JOUR

T1 - Cisapride in chronic idiopathic constipation

T2 - clinical response and effect on colonic transit time.

AU - Bak, Young-Tae

AU - Kim, J. H.

AU - Lee, C. H.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - OBJECTIVES: To evaluate the effect of cisapride on the total and segmental colonic transit times (CTT's) and on the clinical symptoms in patients with chronic idiopathic constipation, and to elucidate whether the correction of the CTT parallels the symptomatic improvement. METHODS: An open prospective trial of cisapride, 10 mg t.i.d. orally for 8 weeks, was done in 25 adult patients (M: F6: 19) with chronic idiopathic constipation of 1 year or longer duration. CTT was measured at baseline and after 8 weeks of cisapride therapy. Frequency, consistency and difficulty in passage of bowel movements were evaluated at baseline and after 2, 4 and 8 weeks of cisapride therapy. RESULTS: 19 cases continued to participate until the end of 4 weeks of therapy and 15 cases completed the entire 8 weeks' trial. No serious side effect was experienced during the study period. Total and right segmental CTT's shortened with 8 weeks of cisapride treatment. Defecation frequency increased and difficulty in stool passage improved with 2 to 8 weeks of treatment. Stool consistency had a tendency toward normal after 8 weeks of treatment (p = 0.06). The global response was excellent in 7 cases (46.7%), good in 5 (33.3%) and poor in 3 (20.0%). If all dropped-out cases were assumed to be poor responders, the good or excellent responders after 8 weeks of cisapride might be 48.0% of all recruited patients. The response to cisapride could not be predicted by the various clinical parameters of the patients. CONCLUSION: Cisapride is an effective drug in at least half of the patients with chronic idiopathic constipation.

AB - OBJECTIVES: To evaluate the effect of cisapride on the total and segmental colonic transit times (CTT's) and on the clinical symptoms in patients with chronic idiopathic constipation, and to elucidate whether the correction of the CTT parallels the symptomatic improvement. METHODS: An open prospective trial of cisapride, 10 mg t.i.d. orally for 8 weeks, was done in 25 adult patients (M: F6: 19) with chronic idiopathic constipation of 1 year or longer duration. CTT was measured at baseline and after 8 weeks of cisapride therapy. Frequency, consistency and difficulty in passage of bowel movements were evaluated at baseline and after 2, 4 and 8 weeks of cisapride therapy. RESULTS: 19 cases continued to participate until the end of 4 weeks of therapy and 15 cases completed the entire 8 weeks' trial. No serious side effect was experienced during the study period. Total and right segmental CTT's shortened with 8 weeks of cisapride treatment. Defecation frequency increased and difficulty in stool passage improved with 2 to 8 weeks of treatment. Stool consistency had a tendency toward normal after 8 weeks of treatment (p = 0.06). The global response was excellent in 7 cases (46.7%), good in 5 (33.3%) and poor in 3 (20.0%). If all dropped-out cases were assumed to be poor responders, the good or excellent responders after 8 weeks of cisapride might be 48.0% of all recruited patients. The response to cisapride could not be predicted by the various clinical parameters of the patients. CONCLUSION: Cisapride is an effective drug in at least half of the patients with chronic idiopathic constipation.

UR - http://www.scopus.com/inward/record.url?scp=0030158510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030158510&partnerID=8YFLogxK

U2 - 10.3904/kjim.1996.11.2.151

DO - 10.3904/kjim.1996.11.2.151

M3 - Article

C2 - 8854652

AN - SCOPUS:0030158510

VL - 11

SP - 151

EP - 156

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 2

ER -